GlassScriptPhysician profile
Yves Jodesty
NPI 1801258140
$685.53
in general payments reported to CMS, 2019-2025
8 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $22.59 · 2023: $128 · 2024: $420 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $474 · Travel and Lodging: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $473.94 |
| Travel and Lodging | $189.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $243.76 | 2024 | |
| Boston Scientific Corporation | $227.97 | 2023-2024 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $68.76 | 2024-2025 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $51.00 | 2020-2025 | Trelegy Ellipta |
| Viatris Specialty LLC | $34.67 | 2025 | Yupelri |
| Astellas Pharma US INC | $27.78 | 2024 | Veozah |
| Lilly USA, LLC | $16.67 | 2023 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.92 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yves Jodesty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.